Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Phase I Study of Bb-10901 (IMGN901, huN901-DM10 in Combination With Lenalidomide and Dexamethasone in Patients With CD56-positive Relapsed or Relapsed/Refractory Multiple Myeloma

NCT00991562 is registered in ClinicalTrials.gov with ImmunoGen, Inc. as lead sponsor.

NCT NCT00991562
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00991562 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Phase I Study of Bb-10901 (IMGN901, huN901-DM10 in Combination With Lenalidomide and Dexamethasone in Patients With CD56-positive Relapsed or Relapsed/Refractory Multiple Myeloma
Lead sponsor
ImmunoGen, Inc.
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2009
Completion date
October 31, 2014
Enrollment
50 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma